Published in Anticancer Drugs on September 01, 2005
New insights into p53 signaling and cancer cell response to DNA damage: implications for cancer therapy. J Biomed Biotechnol (2012) 1.57
Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells. J Nanobiotechnology (2015) 1.52
Targeting tumor metabolism with 2-deoxyglucose in patients with castrate-resistant prostate cancer and advanced malignancies. Prostate (2010) 1.45
Akt inhibitors as an HIV-1 infected macrophage-specific anti-viral therapy. Retrovirology (2008) 1.44
Saccharomyces cerevisiae Sit4 phosphatase is active irrespective of the nitrogen source provided, and Gln3 phosphorylation levels become nitrogen source-responsive in a sit4-deleted strain. J Biol Chem (2006) 1.23
Akt1 is necessary for the vascular maturation and angiogenesis during cutaneous wound healing. Angiogenesis (2008) 1.20
Tor pathway control of the nitrogen-responsive DAL5 gene bifurcates at the level of Gln3 and Gat1 regulation in Saccharomyces cerevisiae. J Biol Chem (2008) 1.17
Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J Cancer Res Clin Oncol (2009) 1.13
The PI3K/AKT/mTOR pathway is activated in gastric cancer with potential prognostic and predictive significance. Virchows Arch (2014) 1.10
In vivo antitumor and antimetastatic activity of sunitinib in preclinical neuroblastoma mouse model. Neoplasia (2009) 1.09
Stress-responsive Gln3 localization in Saccharomyces cerevisiae is separable from and can overwhelm nitrogen source regulation. J Biol Chem (2007) 1.09
A new approach for prediction of tumor sensitivity to targeted drugs based on functional data. BMC Bioinformatics (2013) 1.05
Apocrine-eccrine carcinomas: molecular and immunohistochemical analyses. PLoS One (2012) 1.01
The cytomegalovirus homolog of interleukin-10 requires phosphatidylinositol 3-kinase activity for inhibition of cytokine synthesis in monocytes. J Virol (2006) 0.99
MiR-218 impairs tumor growth and increases chemo-sensitivity to cisplatin in cervical cancer. Int J Mol Sci (2012) 0.99
Molecular targeted agents for gastric and gastroesophageal junction cancer. Surg Today (2011) 0.97
ErbB signaling in cardiac development and disease. Semin Cell Dev Biol (2010) 0.95
Ammonia-specific regulation of Gln3 localization in Saccharomyces cerevisiae by protein kinase Npr1. J Biol Chem (2006) 0.93
Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation. Mol Cancer (2011) 0.93
Analysis of the expression of biomarkers in urinary bladder cancer using a tissue microarray. Mol Carcinog (2008) 0.92
Overexpression of DJ-1 and HSP90α, and loss of PTEN associated with invasive urothelial carcinoma of urinary bladder: Possible prognostic markers. Oncol Lett (2011) 0.92
Microarray-assisted pathway analysis identifies MT1X & NFκB as mediators of TCRP1-associated resistance to cisplatin in oral squamous cell carcinoma. PLoS One (2012) 0.91
PKM2: the thread linking energy metabolism reprogramming with epigenetics in cancer. Int J Mol Sci (2014) 0.90
The macrophage: a therapeutic target in HIV-1 infection. Mol Cell Ther (2014) 0.90
Activation of Akt/mTOR pathway is associated with poor prognosis of nasopharyngeal carcinoma. PLoS One (2014) 0.90
Second-line strategies for metastatic renal cell carcinoma: classics and novel approaches. J Cancer Res Clin Oncol (2005) 0.89
miR-101-2, miR-125b-2 and miR-451a act as potential tumor suppressors in gastric cancer through regulation of the PI3K/AKT/mTOR pathway. Cell Oncol (Dordr) (2015) 0.89
STI571 sensitizes breast cancer cells to 5-fluorouracil, cisplatin and camptothecin in a cell type-specific manner. Biochem Pharmacol (2009) 0.88
Identifying molecular targets of lifestyle modifications in colon cancer prevention. Front Oncol (2013) 0.87
miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN. Nat Commun (2016) 0.87
Potent dual inhibitors of TORC1 and TORC2 complexes (KU-0063794 and KU-0068650) demonstrate in vitro and ex vivo anti-keloid scar activity. J Invest Dermatol (2013) 0.86
The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells. Cancer Gene Ther (2014) 0.86
Combining mTOR inhibition with radiation improves antitumor activity in bladder cancer cells in vitro and in vivo: a novel strategy for treatment. PLoS One (2013) 0.86
Cell proliferation and apoptosis in rat mammary glands following combinational exposure to bisphenol A and genistein. BMC Cancer (2014) 0.86
Down-Regulated NRSN2 Promotes Cell Proliferation and Survival Through PI3K/Akt/mTOR Pathway in Hepatocellular Carcinoma. Dig Dis Sci (2015) 0.85
Crosstalk between the AMP-activated kinase and insulin signaling pathways rescues murine blastocyst cells from insulin resistance. Reproduction (2008) 0.85
Proteomic response to 5,6-dimethylxanthenone 4-acetic acid (DMXAA, vadimezan) in human non-small cell lung cancer A549 cells determined by the stable-isotope labeling by amino acids in cell culture (SILAC) approach. Drug Des Devel Ther (2015) 0.85
Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression. BMC Cancer (2011) 0.84
Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro. Chin J Cancer Res (2014) 0.84
Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K/Akt/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells. Drug Des Devel Ther (2015) 0.84
Plumbagin elicits differential proteomic responses mainly involving cell cycle, apoptosis, autophagy, and epithelial-to-mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells. Drug Des Devel Ther (2015) 0.84
Selective anticancer agents suppress aging in Drosophila. Oncotarget (2013) 0.84
A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth. Cancer Prev Res (Phila) (2010) 0.83
Combined effects of PI3K and SRC kinase inhibitors with imatinib on intracellular calcium levels, autophagy, and apoptosis in CML-PBL cells. Cell Cycle (2013) 0.83
Epidermal growth factor and aging: a signaling molecule reveals a new eye opening function. Aging (Albany NY) (2011) 0.83
Regulating aging in adult stem cells with microRNA. Z Gerontol Geriatr (2013) 0.82
Longikaurin E induces apoptosis of pancreatic cancer cells via modulation of the p38 and PI3K/AKT pathways by ROS. Naunyn Schmiedebergs Arch Pharmacol (2015) 0.81
Heteronemin, a Spongean Sesterterpene, Induces Cell Apoptosis and Autophagy in Human Renal Carcinoma Cells. Biomed Res Int (2015) 0.81
Role of TM4SF1 in regulating breast cancer cell migration and apoptosis through PI3K/AKT/mTOR pathway. Int J Clin Exp Pathol (2015) 0.81
Transcriptomic changes induced by mycophenolic acid in gastric cancer cells. Am J Transl Res (2013) 0.81
Trilayer micelles for combination delivery of rapamycin and siRNA targeting Y-box binding protein-1 (siYB-1). Biomaterials (2013) 0.81
Baicalein inhibits prostate cancer cell growth and metastasis via the caveolin-1/AKT/mTOR pathway. Mol Cell Biochem (2015) 0.81
MicroRNA-147 suppresses proliferation, invasion and migration through the AKT/mTOR signaling pathway in breast cancer. Oncol Lett (2015) 0.81
A novel piperazine derivative potently induces caspase-dependent apoptosis of cancer cells via inhibition of multiple cancer signaling pathways. Am J Transl Res (2013) 0.80
Predominant Activation of JAK/STAT3 Pathway by Interleukin-6 Is Implicated in Hepatocarcinogenesis. Neoplasia (2015) 0.80
mTOR pathway is activated by PKA in adrenocortical cells and participates in vivo to apoptosis resistance in primary pigmented nodular adrenocortical disease (PPNAD). Hum Mol Genet (2014) 0.80
Targeting vascular endothelial growth factor (VEGF)-receptor-signaling in renal cell carcinoma. World J Urol (2007) 0.80
Delineation of biological and molecular mechanisms underlying the diverse anticancer activities of mycophenolic acid. Int J Clin Exp Pathol (2013) 0.79
TRPV1-antagonist AMG9810 promotes mouse skin tumorigenesis through EGFR/Akt signaling. Carcinogenesis (2011) 0.79
Melatonin combined with endoplasmic reticulum stress induces cell death via the PI3K/Akt/mTOR pathway in B16F10 melanoma cells. PLoS One (2014) 0.79
Thrombin-mediated activation of Akt signaling contributes to pulmonary vascular remodeling in pulmonary hypertension. Physiol Rep (2013) 0.79
Resveratrol inhibits the phosphatidylinositide 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway in the human chronic myeloid leukemia K562 cell line. Oncol Lett (2014) 0.79
The dual PI3K/mTOR inhibitor NVP-BEZ235 inhibits proliferation and induces apoptosis of burkitt lymphoma cells. Cancer Cell Int (2015) 0.78
Antiproliferative effect of the methanol extract from the roots of Petasites japonicus on Hep3B hepatocellular carcinoma cells in vitro and in vivo. Exp Ther Med (2015) 0.78
Cellular senescence and aging: the role of B-MYB. Aging Cell (2014) 0.78
p-AKT overexpression in primary renal cell carcinomas and their metastases. Clin Exp Metastasis (2010) 0.78
3,3'-diindolylmethane rapidly and selectively inhibits hepatocyte growth factor/c-Met signaling in breast cancer cells. J Nutr Biochem (2013) 0.78
Natural product-based nanomedicine: recent advances and issues. Int J Nanomedicine (2015) 0.78
New knowledge of the mechanisms of sorafenib resistance in liver cancer. Acta Pharmacol Sin (2017) 0.77
Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma. Oncotarget (2016) 0.77
Chemopreventive drugs: mechanisms via inhibition of cancer stem cells in colorectal cancer. World J Gastroenterol (2014) 0.77
Immune surveillance of nasopharyngeal carcinoma (NpC). Bioinformation (2011) 0.77
Choline plasmalogens isolated from swine liver inhibit hepatoma cell proliferation associated with caveolin-1/Akt signaling. PLoS One (2013) 0.76
Inhibition of β-Catenin to Overcome Endocrine Resistance in Tamoxifen-Resistant Breast Cancer Cell Line. PLoS One (2016) 0.75
Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options. Cancer Manag Res (2015) 0.75
Osteopontin is Critical for Hyperactive mTOR-Induced Tumorigenesis in Oral Squamous Cell Carcinoma. J Cancer (2017) 0.75
A Review of mTOR Pathway Inhibitors in Gynecologic Cancer. Oxid Med Cell Longev (2017) 0.75
PI3K-PTEN dysregulation leads to mTOR-driven upregulation of the core clock gene BMAL1 in normal and malignant epithelial cells. Oncotarget (2016) 0.75
The PIK3/mTOR dual inhibitor BEZ235 suppresses proliferation and migration and reverses multidrug resistance in acute myeloid leukemia. Acta Pharmacol Sin (2017) 0.75
Tangeretin derivative, 5-acetyloxy-6,7,8,4'-tetramethoxyflavone induces G2/M arrest, apoptosis and autophagy in human non-small cell lung cancer cells in vitro and in vivo. Cancer Biol Ther (2016) 0.75
Inhibition of mammalian target of rapamycin by rapamycin increases the radiosensitivity of esophageal carcinoma Eca109 cells. Oncol Lett (2014) 0.75
Macrophage migration inhibitory factor promotes cardiac stem cell proliferation and endothelial differentiation through the activation of the PI3K/Akt/mTOR and AMPK pathways. Int J Mol Med (2016) 0.75
ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines. Oncotarget (2016) 0.75
Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines. Drug Des Devel Ther (2017) 0.75
PCI-24781 down-regulates EZH2 expression and then promotes glioma apoptosis by suppressing the PIK3K/Akt/mTOR pathway. Genet Mol Biol (2014) 0.75
Proliferation and invasion of ovarian cancer cells are suppressed by knockdown of TRIM11. Oncol Lett (2017) 0.75
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Pharmacogenomics--drug disposition, drug targets, and side effects. N Engl J Med (2003) 7.23
Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol (2004) 5.12
Genomics and drug response. N Engl J Med (2011) 4.35
Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer. J Clin Oncol (2007) 3.86
UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J Natl Cancer Inst (2007) 3.85
A high-resolution map of segmental DNA copy number variation in the mouse genome. PLoS Genet (2006) 3.24
Beta2-adrenergic receptor genotype and survival among patients receiving beta-blocker therapy after an acute coronary syndrome. JAMA (2005) 3.16
Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost (2004) 2.64
Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol (2011) 2.47
Genome-wide discovery of loci influencing chemotherapy cytotoxicity. Proc Natl Acad Sci U S A (2004) 2.37
CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer (2009) 2.32
Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype. Thromb Haemost (2005) 2.25
CpG island methylation of DNA damage response genes in advanced ovarian cancer. Cancer Res (2005) 2.11
Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther (2009) 2.10
Pharmacogenomics: challenges and opportunities. Ann Intern Med (2006) 1.96
Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys (2009) 1.95
Genomic medicine: a decade of successes, challenges, and opportunities. Sci Transl Med (2013) 1.89
Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther (2006) 1.82
Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis. J Rheumatol (2008) 1.81
Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin Pharmacokinet (2005) 1.75
Knockdown of RNA binding protein musashi-1 leads to tumor regression in vivo. Gastroenterology (2008) 1.68
Japanese-US common-arm analysis of paclitaxel plus carboplatin in advanced non-small-cell lung cancer: a model for assessing population-related pharmacogenomics. J Clin Oncol (2009) 1.61
A mouse-based strategy for cyclophosphamide pharmacogenomic discovery. J Appl Physiol (1985) (2003) 1.55
Pyrosequencing of clinically relevant polymorphisms. Methods Mol Biol (2005) 1.52
A genome-wide association study identifies novel loci for paclitaxel-induced sensory peripheral neuropathy in CALGB 40101. Clin Cancer Res (2012) 1.50
Pharmacogenomic discovery approaches: will the real genes please stand up? J Clin Oncol (2005) 1.49
wuHMM: a robust algorithm to detect DNA copy number variation using long oligonucleotide microarray data. Nucleic Acids Res (2008) 1.48
Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial. J Natl Cancer Inst (2012) 1.46
Pharmacogenomics of cancer chemotherapy-induced toxicity. J Support Oncol (2007) 1.46
Irinotecan pathway genotype analysis to predict pharmacokinetics. Clin Cancer Res (2003) 1.42
Disulfiram-mediated inhibition of NF-kappaB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. Int J Cancer (2003) 1.41
Comment on "A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502d7 that demethylates codeine to morphine", J Biol Chem 279: 27383-27389. Drug Metab Dispos (2005) 1.38
CANDID: a flexible method for prioritizing candidate genes for complex human traits. Genet Epidemiol (2008) 1.36
Cancer pharmacogenetics: polymorphisms, pathways and beyond. Nat Rev Cancer (2003) 1.36
Pharmacogenomic characterization of US FDA-approved cytotoxic drugs. Pharmacogenomics (2011) 1.34
Carbamazepine, HLA-B*1502 and risk of Stevens-Johnson syndrome and toxic epidermal necrolysis: US FDA recommendations. Pharmacogenomics (2008) 1.33
Racial differences in advanced colorectal cancer outcomes and pharmacogenetics: a subgroup analysis of a large randomized clinical trial. J Clin Oncol (2009) 1.32
Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. Cancer Res (2006) 1.31
Human carboxylesterase 2 is commonly expressed in tumor tissue and is correlated with activation of irinotecan. Clin Cancer Res (2002) 1.31
Cancer pharmacogenomics and pharmacoepidemiology: setting a research agenda to accelerate translation. J Natl Cancer Inst (2010) 1.30
Pharmacogenomics: from bedside to clinical practice. Hum Mol Genet (2006) 1.28
Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis. Arthritis Rheum (2006) 1.27
PharmGKB summary: methotrexate pathway. Pharmacogenet Genomics (2011) 1.27
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303. Clin Cancer Res (2011) 1.26
Creating and evaluating genetic tests predictive of drug response. Nat Rev Drug Discov (2008) 1.24
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat (2012) 1.23
A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT. Pharmacogenet Genomics (2012) 1.23
Genetic and clinical factors relating to warfarin dosing. Trends Pharmacol Sci (2009) 1.21
Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur J Cancer (2007) 1.21
Tamoxifen and CYP2D6: a contradiction of data. Oncologist (2012) 1.21
Irinotecan pharmacogenetics: influence of pharmacodynamic genes. Clin Cancer Res (2008) 1.20
Genetic variation in the B-type natiuretic peptide pathway affects BNP levels. Cardiovasc Drugs Ther (2007) 1.18
Analysis of key cell-cycle checkpoint proteins in colorectal tumours. J Pathol (2002) 1.17
PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics (2011) 1.16
ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition. Clin Cancer Res (2004) 1.16
Cancer pharmacogenomics: current and future applications. Biochim Biophys Acta (2003) 1.15
PromoLign: a database for upstream region analysis and SNPs. Hum Mutat (2004) 1.15
Diflomotecan pharmacokinetics in relation to ABCG2 421C>A genotype. Clin Pharmacol Ther (2004) 1.13
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res (2005) 1.13
Validation of clinical testing for warfarin sensitivity: comparison of CYP2C9-VKORC1 genotyping assays and warfarin-dosing algorithms. J Mol Diagn (2009) 1.12
PolyMAPr: programs for polymorphism database mining, annotation, and functional analysis. Hum Mutat (2005) 1.12
Pharmacogenomic assessment of carboxylesterases 1 and 2. Genomics (2004) 1.09
Polymorphism discovery in 51 chemotherapy pathway genes. Hum Mol Genet (2005) 1.09
Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin Cancer Res (2004) 1.09
Pharmacogenomic genome-wide association studies: lessons learned thus far. Pharmacogenomics (2009) 1.08
Distribution of ITPA P32T alleles in multiple world populations. J Hum Genet (2004) 1.07
Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations. Pharmacogenomics (2009) 1.07
Structure and characterization of human carboxylesterase 1A1, 1A2, and 1A3 genes. Pharmacogenet Genomics (2008) 1.07
The kinetics and tissue distribution of protein transduction in mice. Eur J Pharm Sci (2006) 1.06
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective. Clin Cancer Res (2006) 1.05
SNP databases and pharmacogenetics: great start, but a long way to go. Hum Mutat (2002) 1.05
Association of thymidylate synthase variants with 5-fluorouracil cytotoxicity. Pharmacogenet Genomics (2009) 1.05
A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther (2004) 1.04
Population pharmacokinetic modeling of the association between 63396C->T pregnane X receptor polymorphism and unboosted atazanavir clearance. Antimicrob Agents Chemother (2010) 1.03
Nomenclature for alleles of the thiopurine methyltransferase gene. Pharmacogenet Genomics (2013) 1.03
Variance in the expression of 5-Fluorouracil pathway genes in colorectal cancer. Clin Cancer Res (2005) 1.02
Characterizing genetic variants for clinical action. Am J Med Genet C Semin Med Genet (2014) 1.02
A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol (2010) 1.01
A health services research agenda for cellular, molecular and genomic technologies in cancer care. Public Health Genomics (2009) 1.01
The candidate oncogene ZNF217 is frequently amplified in colon cancer. J Pathol (2004) 1.01
Concordance of pharmacogenetic markers in germline and colorectal tumor DNA. Pharmacogenomics (2005) 1.00
Pharmacogenetics and oncology treatment for breast cancer. Expert Opin Pharmacother (2007) 1.00
Implementation of a pharmacogenomics service in a community pharmacy. J Am Pharm Assoc (2003) (2014) 1.00
Identification and replication of loci involved in camptothecin-induced cytotoxicity using CEPH pedigrees. PLoS One (2011) 1.00
Genome-wide association and pharmacological profiling of 29 anticancer agents using lymphoblastoid cell lines. Pharmacogenomics (2014) 1.00
Beta-2 adrenergic receptor genotypes and haplotypes in different ethnic groups. Int J Mol Med (2005) 1.00
Gene expression profiling of the irinotecan pathway in colorectal cancer. Clin Cancer Res (2005) 1.00
Ability of whole-genome SNP arrays to capture 'must have' pharmacogenomic variants. Pharmacogenomics (2008) 0.99
CYP3A4 and CYP3A5 genotyping by Pyrosequencing. BMC Med Genet (2005) 0.99
Can inhibiting dihydropyrimidine dehydrogenase limit hand-foot syndrome caused by fluoropyrimidines? Clin Cancer Res (2008) 0.99
Genomic profiling in CEPH cell lines distinguishes between the camptothecins and indenoisoquinolines. Mol Cancer Ther (2011) 0.98
Economic opportunities and challenges for pharmacogenomics. Annu Rev Pharmacol Toxicol (2010) 0.97
Defining the opportunity for pharmacogenetic intervention in primary care. Pharmacogenomics (2006) 0.97
Copy-number analysis of topoisomerase and thymidylate synthase genes in frozen and FFPE DNAs of colorectal cancers. Pharmacogenomics (2008) 0.97
Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms. Am J Clin Pathol (2005) 0.96
Multivariate methods and software for association mapping in dose-response genome-wide association studies. BioData Min (2012) 0.96
Copy number variants in pharmacogenetic genes. Trends Mol Med (2011) 0.96
Implications of genome-wide association studies in cancer therapeutics. Br J Clin Pharmacol (2013) 0.96